Novel coronavirus inactivated vaccine is a novel coronavirus vaccine developed by Sinopharm China Bio-Beijing Institute of Biological Products Co., Ltd., which is suitable for preventing diseases caused by novel coronavirus infection (coronavirus pneumonia-19).
On June 5438+February 3, 2020, the joint prevention and control mechanism of the State Council released that the COVID-19 inactivated vaccine of Sinopharm Group China Bio has been approved for conditional marketing by the State Pharmaceutical Administration, and the protection effect meets the requirements of the relevant standards of the World Health Organization and the State Pharmaceutical Administration, and will be provided to the whole people free of charge in the future. Up to 20021120, more than150,000 people have been vaccinated in China.
Information about vaccines in COVID-19:
1, 65438+February 3, 20201,released by the joint prevention and control mechanism of the State Council, and the inactivated COVID-19 vaccine of Sinopharm China has been approved for conditional listing by the State Pharmaceutical Administration. Existing data show that the protection rate is 79.34%.
2. With the intensive reports of sporadic cases and cluster epidemics in many provinces in China, the number of high-risk areas in China has increased, and the emergency vaccination of COVID-19 vaccine for key populations has been accelerated in many places. Beijing, Zhejiang, Shaanxi and other places have indicated that COVID-19 vaccination will be completed before the Spring Festival.